Pfizer Inc. (PFE) Announces Positive Results From its Phase 3 HER2CLIMB-05 Trial

​Pfizer Inc. (NYSE:PFE) is one of the Best Growth Stocks Under $25 to Buy Right Now. On October 14, Pfizer Inc. (NYSE:PFE) announced positive results from its Phase 3 HER2CLIMB-05 trial.

​The trial tested the kinase inhibitor TUKYSA with first-line combination therapy for patients with human epidermal growth factor receptor 2-positive (HER2+) metastatic breast cancer. The trial met its endpoints, demonstrating significant improvement in progression-free survival against the placebo.

​Management noted that HER2+ breast cancer is a challenging type of cancer with many patients experiencing disease progression despite effective treatments. The results from this trial suggest that HER2CLIMB-05, along with TUKYSA, has the ability to stop disease progression, while maintaining a healthy safety profile.

​Pfizer Inc. (NYSE:PFE) is a global biopharmaceutical company focused on discovering, developing, manufacturing, and marketing medicines.

While we acknowledge the potential of PFE as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.